Factors influencing the use of tocilizumab as monotherapy in patients with rheumatoid arthritis in a real-life setting: results at 1 year of the ACT-SOLO study

INTRODUCTION: Using a biologic disease-modifying antirheumatic drug (bDMARD) as monotherapy in clinical practice for patients with rheumatoid arthritis (RA) is common and recognised by health authorities although current guidelines recommend to combine them with conventional synthetic (cs)DMARDs. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Flipo, René-Marc, Maillefert, Jean-Francis, Chazerain, Pascal, Idier, Isabelle, Coudert, Mathieu, Tebib, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Rheumatoid Arthritis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237763/
https://www.ncbi.nlm.nih.gov/pubmed/28123778
http://dx.doi.org/10.1136/rmdopen-2016-000340

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5237763/
https://www.ncbi.nlm.nih.gov/pubmed/28123778
http://dx.doi.org/10.1136/rmdopen-2016-000340

Ejemplares similares